Tailian Teneligliptin Hydrobromide Tablets

1. Indications and Usage
Glycemic Control: Indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus, either as monotherapy or in combination with metformin.
2. Dosage and Administration
Route of Administration: Oral administration.
Recommended Dosage: The usual recommended dose for adults is 20 mg once daily. If glycemic control is inadequate, the dose may be increased to 40 mg once daily after careful observation.
Administration Details: The timing of administration relative to meals does not significantly affect absorption, so it can be taken with or without food.
Renal/Hepatic Impairment: Dose adjustment is generally not required for patients with mild to moderate renal or hepatic impairment. Clinical safety has not been established in patients with severe hepatic impairment or heart failure (NYHA class III-IV).
3. Mechanism of Action
DPP-4 Inhibition: Teneligliptin selectively inhibits dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for degrading incretin hormones (GLP-1 and GIP).
Glucose Regulation: By inhibiting DPP-4, active incretin levels are increased, stimulating glucose-dependent insulin secretion and suppressing glucagon release, thereby lowering blood glucose levels.
4. Safety and Warnings
Hypoglycemia: When used alone, the risk is low. However, concomitant use with insulin or sulfonylureas increases the risk of hypoglycemia, and dose reductions of the concomitant agents may be necessary.
Acute Pancreatitis: Post-marketing reports of acute pancreatitis have been observed. Patients should be monitored for symptoms of persistent severe abdominal pain and vomiting.
QT Prolongation: QTc prolongation has been reported with high doses in clinical trials. Caution is advised in patients with a history of QT prolongation or arrhythmias.
Hypersensitivity: Discontinue if signs of severe hypersensitivity reactions, such as angioedema, urticaria, or severe skin eruptions, occur.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: The most frequently reported adverse reactions include constipation, abdominal discomfort, nausea, hypoglycemia, and upper respiratory tract infections.
Clinical Research Highlights: Clinical trials have demonstrated that teneligliptin significantly reduces HbA1c and fasting plasma glucose levels compared to placebo, with a low risk of weight gain.
6. Drug Interactions
Insulin and Sulfonylureas: Concomitant use may increase the risk of hypoglycemia; dose adjustments may be required.
Metformin: No significant pharmacokinetic interaction is expected, and the combination is commonly used without dose adjustment.
CYP3A4 Inhibitors: Since teneligliptin is partially metabolized by CYP3A4, strong inhibitors of this enzyme may increase plasma concentrations, although clinical significance is low.
7. Pharmaceutical Information
Chemical Composition: Active ingredient: Teneligliptin hydrobromide.
Appearance: The tablets are film-coated and may appear pale red or off-white depending on the coating.
Packaging: Available in various pack sizes (e.g., 20 mg or 40 mg strengths).
Storage: Store at controlled room temperature (15°C to 30°C); protect from moisture.